{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:04:40Z","timestamp":1790845480595,"version":"4.1.0"},"reference-count":92,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cardiovascular disease (CVD) accounts for &gt;17 million deaths globally every year, and this figure is predicted to rise to &gt;23 million by 2030. Numerous studies have explored the relationship between cholesterol and CVD and there is now consensus that dyslipidaemia is a causal factor in the pathogenesis of atherosclerosis. Statins have become the cornerstone of the management of dyslipidaemia. Statins have proved to have a very good safety profile. The risk of adverse events is small compared to the benefits. Nevertheless, the potential risk of an adverse event occurring must be considered when prescribing and monitoring statin therapy to individual patients. Statin-associated muscle disease (SAMS) is by far the most studied and the most common reason for discontinuation of therapy. The reported incidence varies greatly, ranging between 5% and 29%. Milder disease is common and the more serious form, rhabdomyolysis is far rarer with an incidence of approximately 1 in 10,000. The pathophysiology of, and mechanisms leading to SAMS, are yet to be fully understood. Literature points towards statin-induced mitochondrial dysfunction as the most likely cause of SAMS. However, the exact processes leading to mitochondrial dysfunction are not yet fully understood. This paper details some of the different aetiological hypotheses put forward, focussing particularly on those related to mitochondrial dysfunction.<\/jats:p>","DOI":"10.3390\/jcm6080075","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T10:04:36Z","timestamp":1500977076000},"page":"75","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Statins, Muscle Disease and Mitochondria"],"prefix":"10.3390","volume":"6","author":[{"given":"Radha","family":"Ramachandran","sequence":"first","affiliation":[{"name":"Departments of Chemical Pathology\/Metabolic Medicine, Guys and St Thomas\u2019 Hospitals NHS Foundation Trust, London SE1 7EH, UK"},{"name":"Adult Inherited Metabolic Diseases, Centre for Inherited Metabolic Diseases, Evelina, Guys and St Thomas\u2019 Hospitals NHS Foundation Trust, Lambeth Palace Road, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wierzbicki","sequence":"additional","affiliation":[{"name":"Departments of Chemical Pathology\/Metabolic Medicine, Guys and St Thomas\u2019 Hospitals NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"ref_1","unstructured":"GBD 2015 Risk Factors Collaborators (2016). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1659\u20131724."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: From plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"ref_3","unstructured":"Ference, B.A., Ginsberg, H.N., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., Hegele, R.A., Krauss, R.M., Raal, F.J., and Schunkert, H. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10654-007-9165-7","article-title":"The emerging risk factors collaboration: Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases","volume":"22","author":"Danesh","year":"2007","journal-title":"Eur. J. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R500014-JLR200","article-title":"The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 coronary primary prevention trial ends it\u2014Almost","volume":"47","author":"Steinberg","year":"2006","journal-title":"J. Lipid. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R600009-JLR200","article-title":"Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy","volume":"47","author":"Steinberg","year":"2006","journal-title":"J. Lipid. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.110.975284","article-title":"Lapaquistat acetate: Development of a squalene synthase inhibitor for the treatment of hypercholesterolemia","volume":"123","author":"Stein","year":"2011","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/2047487313483600","article-title":"Dose-comparative effects of different statins on serum lipid levels: A network meta-analysis of 256,827 individuals in 181 randomized controlled trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"The Scandinavian Simvastatin Survival Study (4S) investigators (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S). Lancet, 344, 1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study Investigators (2002). MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10408447109104302","article-title":"The cataractogenic activity of chemical agents","volume":"1","author":"Gehring","year":"1971","journal-title":"CRC Crit. Rev. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/j.1742-1241.2008.01884.x","article-title":"Statin safety and chronic liver disease","volume":"62","author":"Cash","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Emberson, J.R., Kearney, P.M., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., and Collins, R. (2012). Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029849"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/heartjnl-2012-302014","article-title":"Predicting the adverse risk of statin treatment: An independent and external validation of Qstatin risk scores in the UK","volume":"98","author":"Collins","year":"2012","journal-title":"Heart"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"(2011). Lessons from Lipitor and the broken blockbuster drug model. Lancet, 378, 1976.","DOI":"10.1016\/S0140-6736(11)61858-8"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejim.2015.01.002","article-title":"Risk identification and possible countermeasures for muscle adverse effects during statin therapy","volume":"26","author":"Magni","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2015.02.042","article-title":"Statin induced necrotizing autoimmune myopathy","volume":"351","author":"Babu","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/HCO.0000000000000282","article-title":"Statin myopathy: Over-rated and under-treated?","volume":"31","author":"Maghsoodi","year":"2016","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_25","first-page":"111","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia\u2014A systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Sahebkar","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/1947-2714.153919","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JND-160184","article-title":"Histopathologic and biochemical evidence for mitochondrial disease among 279 patients with severe statin myopathy","volume":"4","author":"Hou","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014The PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: A cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248414529622","article-title":"Addressing statin adverse effects in the clinic: The 5 Ms","volume":"19","author":"Katz","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance\u2014An attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/gim.2014.41","article-title":"Genetic factors affecting statin concentrations and subsequent myopathy: A HuGENet systematic review","volume":"16","author":"Canestaro","year":"2014","journal-title":"Genet. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.cmet.2015.03.003","article-title":"GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals","volume":"21","author":"Luzum","year":"2015","journal-title":"Cell Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","article-title":"Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation","volume":"39","author":"Tay","year":"2008","journal-title":"Pediatr. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome","volume":"94","author":"Chariot","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_44","first-page":"35","article-title":"Mitochondrial dysfunction and chronic disease: Treatment with natural supplements","volume":"13","author":"Nicolson","year":"2014","journal-title":"Integr. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: Mechanism of action","volume":"175","author":"Roederer","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/eci.12461","article-title":"The role of mitochondria in statin-induced myopathy","volume":"45","author":"Apostolopoulou","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1373\/clinchem.2005.054643","article-title":"Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard","volume":"51","author":"Duncan","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4615-2912-5_11","article-title":"Distribution, biosynthesis, and function of mevalonate pathway lipids","volume":"21","author":"Ericsson","year":"1993","journal-title":"Subcell. Biochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-014-9749-9","article-title":"Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency","volume":"38","author":"Desbats","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: A meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0163-7258(03)00055-X","article-title":"The lipid and non-lipid effects of statins","volume":"99","author":"Wierzbicki","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.mito.2007.03.002","article-title":"Coenzyme Q10 and statins: Biochemical and clinical implications","volume":"7","author":"Littarru","year":"2007","journal-title":"Mitochondrion"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","article-title":"Simvastatin effects on skeletal muscle: Relation to decreased mitochondrial function and glucose intolerance","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/00002018-200528080-00002","article-title":"The effect of HMG-CoA reductase inhibitors on coenzyme Q10, Possible biochemical\/clinical implications","volume":"28","author":"Hargreaves","year":"2005","journal-title":"Drug Saf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jpeds.2010.08.015","article-title":"Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia","volume":"158","author":"Avis","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/15376510802305047","article-title":"Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment","volume":"19","author":"Duncan","year":"2009","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000187521","article-title":"Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin","volume":"65","author":"Arnadottir","year":"1993","journal-title":"Nephron"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"G4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: Summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2012.12.023","article-title":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","volume":"325","author":"Stringer","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbamcr.2011.07.019","article-title":"Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt","volume":"1813","author":"Mullen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00204-014-1378-4","article-title":"Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo","volume":"90","author":"Bonifacio","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A \u2019mitohormesis\u2019 mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2013.04.009","article-title":"Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: Implications for statin-induced rhabdomyolysis","volume":"711","author":"Vaughan","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"16260","DOI":"10.1073\/pnas.0607795103","article-title":"PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription","volume":"103","author":"Sandri","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Goodman, C.A., Pol, D., Zacharewicz, E., Lee-Young, R.S., Snow, R.J., Russell, A.P., and McConell, G.K. (2015). Statin-induced increases in atrophy gene expression occur independently of changes in PGC1alpha protein and mitochondrial content. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128398"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: Distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/0192623307311412","article-title":"Rosuvastatin: Characterization of induced myopathy in the rat","volume":"36","author":"Westwood","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1126\/science.305.5684.637","article-title":"Peering under the hood of Africa\u2019s runners","volume":"305","author":"Holden","year":"2004","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/01.RES.0000097262.21507.DF","article-title":"Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes","volume":"93","author":"Jones","year":"2003","journal-title":"Circ. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","article-title":"Toxicity of statins on rat skeletal muscle mitochondria","volume":"63","author":"Kaufmann","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbrc.2005.10.108","article-title":"Simvastatin induces impairment in skeletal muscle while heart is protected","volume":"338","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","article-title":"What is a relevant statin concentration in cell experiments claiming pleiotropic effects?","volume":"72","author":"Lindh","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1212\/01.WNL.0000042050.85041.FB","article-title":"Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil","volume":"60","author":"Arenas","year":"2003","journal-title":"Neurology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2011.12.007","article-title":"Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation","volume":"202","author":"Mans","year":"2012","journal-title":"Neuroscience"},{"key":"ref_80","first-page":"737","article-title":"Rhabdomyolysis and cerivastatin: Was it a problem of dose?","volume":"167","author":"Kalaria","year":"2002","journal-title":"CMAJ"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/dmd.30.3.225","article-title":"Structural characterization of in vivo rat glutathione adducts and a hydroxylated metabolite of simvastatin hydroxy acid","volume":"30","author":"Subramanian","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1006\/bbrc.1994.2112","article-title":"Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors","volume":"202","author":"Nakahara","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1254\/jphs.93.279","article-title":"Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers","volume":"93","author":"Inoue","year":"2003","journal-title":"J. Pharmacol. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arthrit. Rheum."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","author":"Marciante","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2353\/ajpath.2010.091140","article-title":"Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle","volume":"177","author":"Draeger","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00228-014-1776-9","article-title":"Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: A population-based case-control study including 1st and 2nd degree relatives","volume":"71","author":"Hedenmalm","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1113\/jphysiol.2012.238022","article-title":"Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents","volume":"590","author":"Mallinson","year":"2012","journal-title":"J. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/dmrr.2601","article-title":"Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: The roles of long chain fatty acids","volume":"31","author":"Sarmidi","year":"2015","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Katzberg","year":"2010","journal-title":"Muscle Nerve"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/6\/8\/75\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:43:59Z","timestamp":1760208239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/6\/8\/75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":92,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8]]}},"alternative-id":["jcm6080075"],"URL":"https:\/\/doi.org\/10.3390\/jcm6080075","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}